Lv41
490 积分 2021-03-12 加入
Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial
3小时前
待确认
Integrating multiple outcomes of first-line immunotherapy-based regimens for advanced hepatocellular carcinoma: A network meta-analysis of phase III trials
1个月前
已完结
Cancer burden and control in China: landscape, trends and challenges
1个月前
已完结
[Phase Ⅱ clinical trial of PD-1 inhibitor combined with chemotherapy for locally advanced resectable oral squamous cell carcinoma]
2个月前
已完结
皖公网安备34019202002308
